Title: Daedeok-net– LegoChem, a new drug biotech dreaming to be the next Gilead

Publication:  Daedeok-net/ Jun Ho Kim

Date: 10 June 2011

Summary

• CEO of LegoChem, Dr. Yong Zu Kim, explained "drug development does not aim for the final products. It goes through several different experiment phases and at every phase, license-out is viable, which increases investment value of the product.”

• CEO Kim emphasizes the words of young Chingiz Khan left before the conquest "a dream of one man is just a dream but a dream of all is a reality".

• CEO Kim said "recent interests of big global companies in bio field is because of its close connection to future food supplies. Since venture and big companies play different parts, government's strategic funding can enhance our possibility."

• LegoChem is expecting a technology evaluation as a first step toward KOSDAQ IPO. CEO Kim said "at end of this year, we would have become a global drug development venture."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).